Physician profile
Hugo E Polanco
NPI 1689776213
$946.22
in general payments reported to CMS, 2019-2025
12 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $792 · 2020: $76.38 · 2021: $19.93 · 2022: $57.91.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $296.65 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $125.00 | 2019 | |
| Pfizer INC. | $117.72 | 2019-2022 | |
| Sunovion Pharmaceuticals INC. | $114.43 | 2019-2020 | |
| Medtronic Vascular, INC. | $113.28 | 2019 | |
| Novartis Pharmaceuticals Corporation | $52.91 | 2019 | |
| Lilly USA, LLC | $35.79 | 2019-2022 | |
| Astellas Pharma US INC | $22.55 | 2019 | |
| Xeris Pharmaceuticals, INC. | $19.93 | 2021 | |
| Novo Nordisk INC | $17.12 | 2020 | |
| Collegium Pharmaceutical, INC. | $15.84 | 2019 | |
| Amgen INC. | $15.00 | 2022 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hugo Polanco listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.